Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes

Summary

Matrix metalloproteinase (MMP)-9 plays an important role in stroke by accelerating matrix degradation, disrupting the blood-brain barrier and increasing infarct size. Dipyridamole is an antiplatelet agent with recognised benefits in ischaemic stroke prevention. In addition to its antiplatelet properties, recent studies have reported that dipyridamole also features anti-inflammatory and anti-oxidant properties. We therefore investigated whether dipyridamole can ameliorate the proinflammatory profile of human monocytes, a source of MMP-9 in stroke, in terms of regulation of MMP-9 activity and expression, and explored underlying mechanisms. Human peripheral blood mononuclear cells (PBMC) and U937 cells were treated with increasing concentrations of dipyridamole (up to 10 µg/ml) for 60 minutes before stimulation with tumour necrosis factor (TNF)-α or phorbol myristate acetate (PMA). Exposure of PBMC and U937 to dipyridamole reduced TNF-α- and PMA-induced MMP-9 activity and protein release as well as MMP-9 mRNA, without significantly affecting the release of TIMP-1. This inhibitory effect was independent of dipyridamole-induced cyclic adeno-sine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) increase. Correspondingly, dipyridamole also significantly inhibited TNF-α-induced nuclear factor (NF)-κB activation and nuclear translocation of the p65 NF-κB subunit through a mechanism involving the inhibition of IkBα degradation and p38 MAPK activation. In conclusion, dipyridamole, at therapeutically achievable concentrations, reduces the expression and release of MMP-9 through a mechanism involving p38 MAPK and NF-κB inhibition. These results indicate that dipyridamole exerts anti-inflammatory properties in human monocytes that may favourably contribute to its actions in the secondary prevention of stroke, independent of its antiplatelet properties.

Keywords

Dipyridamole - macrophages - matrix metalloproteinase - MMP-9 - nuclear factor-κB - p38 MAP kinase - stroke

^* The first two authors contributed equally to the study.

• References

• 1 del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischaemic stroke. Thromb Res 2000; 98: 73-81.
• 2 Gidday JM, Gasche YG, Copin JC. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischaemia. Am J Physiol Heart Circ Physiol 2005; 289: H558-568.
• 3 Kim HH, Liao JK. Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39-42.
• 4 Gresele P, Arnout J, Deckmyn H. et al. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-18.
• 5 Diener HC, Cunha L, Forbes C. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
• 6 Halkes PH, van Gijn J, Kappelle LJ. et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
• 7 Chairangsarit P, Sithinamsuwan P, Niyasom S. et al. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischaemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. J Med Assoc Thai 2005; 88 (Suppl. 03) S148-154.
• 8 Weyrich AS, Denis MM, Kuhlmann-Eyre JR. et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005; 111: 633-642.
• 9 Carluccio MA, Siculella L, Ancora MA. et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003; 23: 622-629.
• 10 Ferreira Jr. OC, Valinsky JE, Sheridan K. et al. Phorbol ester-induced differentiation of U937 cells enhances attachment to fibronectin and distinctly modulates the alpha 5 beta 1 and alpha 4 beta 1 fibronectin receptors. Exp Cell Res 1991; 193: 20-26.
• 11 Schreiber EP, Matthias P, Muller MM. et al. Rapid detection of octamer binding proteins with “miniextracts” prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419-6426.
• 12 Chakrabarti S, Blair P, Wu C. et al. Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects. J Cardiovasc Pharmacol 2007; 50: 449-457.
• 13 Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-2114.
• 14 Wang X, Lee SR, Arai K. et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 09: 1313-1317.
• 15 Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993; 08: 395-405.
• 16 Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-5973.
• 17 Palmer S, Chen YH. Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription. Immunol Res 2008; 42: 210-218.
• 18 Nolan GP, Fujita T, Bhatia K. et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 1993; 13: 3557-3566.
• 19 Gamboa A, Abraham R, Diedrich A. et al. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke 2005; 36: 2170-2175.
• 20 Alvarez-Sabin J, Delgado P, Abilleira S. et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004; 35: 1316-1322.
• 21 Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-834.
• 22 Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischaemic stroke. Neurobiol Dis 2008; 32: 200-219.
• 23 Svedin P, Hagberg H, Savman K. et al. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischaemia. J Neurosci 2007; 27: 1511-1518.
• 24 Gough PJ, Gomez IG, Wille PT. et al. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006; 116: 59-69.
• 25 Kouwenhoven M, Carlstrom C, Ozenci V. et al. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001; 21: 365-375.
• 26 Tang Y, Xu H, Du X. et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischaemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006; 26: 1089-1102.
• 27 Guo S, Stins M, Ning M. et al. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis 2010; 30: 290-296.
• 28 Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.
• 29 Barone FC, Arvin B, White RF. et al. Tumor necrosis factor-alpha. A mediator of focal ischaemic brain injury. Stroke 1997; 28: 1233-1244.
• 30 Martin-Villalba A, Hahne M, Kleber S. et al. Therapeutic neutralisation of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 08: 679-686.
• 31 Chakraborti S, Mandal M, Das S. et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-285.
• 32 Irving EA, Barone FC, Reith AD. et al. Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 2000; 77: 65-75.
• 33 Harada J, Sugimoto M. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Jpn J Pharmacol 1999; 79: 369-378.
• 34 Legos JJ, Erhardt JA, White RF. et al. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischaemia. Brain Res 2001; 892: 70-77.
• 35 Chen TH, Kao YC, Chen BC. et al. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Eur J Pharmacol 2006; 541: 138-146.
• 36 Hashimoto S, Gon Y, Matsumoto K. et al. N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br J Pharmacol 2001; 132: 270-276.
• 37 Rajagopalan S, Meng XP, Ramasamy S. et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
• 38 Kusmic C, Petersen C, Picano E. et al. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J Cardiovasc Pharmacol 2000; 36: 141-145.
• 39 Sacco RL, Diener HC, Yusuf S. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
• 40 Eisert W. Cilostazol and Dipyridamole - More than weak inhibition of platelets. In: Therapeutic Advances in Thrombosis. Wyley-Blackwell,; New York: 2012